ReviewTherapeutic advances in respiratory disease
Respiratory viral infections in the elderly.
Review in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Pooled it
- Article
- Global Viral Lower Respiratory Disease Episodes, Hospitalisations, and Clinical Outcomes by Aetiology, 2010-2021.Infectious diseases and therapy · 2026Article
- Characteristics and outcomes of adult patients hospitalised with RSV infection, influenza or COVID-19 in Belgium, winter seasons 2023/24 and 2024/25.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Article
- Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK).Virus research · 2026Article
- Trends of severe human metapneumovirus infections in India.BMC infectious diseases · 2026Article
- Characteristics and Risk Factors Associated With Hospitalization and Severe Disease in Patients Aged ≥ 60 Years With Human Metapneumovirus Infection Over Three Consecutive Seasons (2021-2024) in Valladolid, Spain. The VALLAVIRUS Study.Influenza and other respiratory viruses · 2026Article
- Is Clinical Outcome Pathogen Related? Characteristics and Outcomes of ICU Patients with Severe Acute Respiratory Infections: Focusing on Respiratory Syncytial Virus, Human Metapneumovirus, Influenza Virus, and Parainfluenza Virus.Journal of intensive care medicine · 2026Article
- Multimorbidity patterns and hospitalizations due to lower respiratory tract infections: a 15-year population-based cohort study.Age and ageing · 2026Article
- Key factors of the deranged antiviral response in elderly patients with COVID-19: a machine-learning analysis.GeroScience · 2026Article
- Acute Respiratory Failure and Ventilatory Support in Hospitalized Adults With Viral Respiratory Infection: A Retrospective Cohort Study.Open forum infectious diseases · 2026Article
- Vaccination Strategies Against Respiratory Pathogens in the Adult Population: A Narrative Review.Vaccines · 2026Review
- Distinct Cytokine Landscapes Induced by Influenza a Virus, RSV, and SARS-CoV-2 in Older Adults (65+) Using an Ex Vivo Whole Blood Stimulation Model.Pathogens (Basel, Switzerland) · 2026Article
- Article
- Immunosenescence and susceptibility to respiratory viruses: a state-of-the-art review.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Nonpharmacological interventions for managing infections in chronic respiratory diseases: a comprehensive overview.Breathe (Sheffield, England) · 2026Review
- Aging and Viral Respiratory Infections: Focus on Vitamin D and Microbiota.BioMed research international · 2026Review
- Advances in Human Metapneumovirus Research: Clinical Impact, Diagnostic Innovations, and Therapeutic Challenges.Pathogens (Basel, Switzerland) · 2025Review
- Developing a Latin American Delphi Consensus on Vaccination for Respiratory Diseases in Older Adults.Annals of geriatric medicine and research · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the global over 60-year-old population predicted to more than double over the next 35 years, caring for this aging population has become a major global healthcare challenge. In 2016 there were over 1 million deaths in >70 year olds due to lower respiratory tract infections; 13-31% of these have been reported to be caused by viruses. Since then, there has been a global COVID-19 pandemic, which has caused over 2.3 million deaths so far; increased age has been shown to be the biggest risk factor for morbidity and mortality. Thus, the burden of respiratory viral infections in the elderly is becoming an increasing unmet clinical need. Particular challenges are faced due to the interplay of a variety of factors including complex multimorbidities, decreased physiological reserve and an aging immune system. Moreover, their atypical presentation of symptoms may lead to delayed necessary care, prescription of additional drugs and prolonged hospital stay. This leads to morbidity and mortality and further nosocomial spread. Clinicians currently have limited access to sensitive detection methods. Furthermore, a lack of effective antiviral treatments means there is little incentive to diagnose and record specific non-COVID-19 viral infections. To meet this unmet clinical need, it is first essential to fully understand the burden of respiratory viruses in the elderly. Doing this through prospective screening research studies for all respiratory viruses will help guide preventative policies and clinical trials for emerging therapeutics. The implementation of multiplex point-of-care diagnostics as a mainstay in all healthcare settings will be essential to understand the burden of respiratory viruses, diagnose patients and monitor outbreaks. The further development of novel targeted vaccinations as well as anti-viral therapeutics and new ways to augment the aging immune system is now also essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.